Ficlatuzumab

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Ficlatuzumab ?
Monoclonal antibody
Type Whole antibody
Source Humanized (from mouse)
Target HGF
Clinical data
Legal status ?
Identifiers
CAS number 1174900-84-5 N
ATC code None
KEGG D10123 N
Chemical data
Formula C6446H9954N1718O2026S46 
Mol. mass 145.41 kDa
 N (what is this?)  (verify)

Ficlatuzumab is a humanized monoclonal antibody designed for the treatment of cancers.[1]

Ficlatuzumab was developed by AVEO Pharmaceuticals. In May 2012, AVEO released results of a Phase II clinical trial comparing gefitinib alone and in combination with ficlatuzamab in treatment-naive Asian patients with non-small cell lung cancer.[2]

References[edit]